As shown in Figure 2F, Kaplan-Meier survival analysis revealed a statistically significant worse prognosis for glioma patients with high AEBP1 (> median level) compared to those with low levels of AEBP1 (< median level) in the RAMBRANDT dataset. This evidence concerns the gene AEBP1 and central nervous system cancer.